Telix Pharmaceuticals Secures Chinese NMPA Acceptance for Illuccix NDA and Exceeds FY25 Revenue Guidance

summarizeSummary

Telix Pharmaceuticals announced the Chinese NMPA's acceptance of its New Drug Application for Illuccix, its prostate cancer imaging agent, opening a significant new market. Concurrently, the company reported achieving its upgraded FY 2025 revenue guidance of US$804 million, driven by strong Q4 performance and the successful U.S. launch of Gozellix.

check_boxKey Events

• Chinese NMPA Accepts Illuccix NDA

  The Chinese National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for TLX591-Px (Illuccix®), Telix's lead prostate cancer imaging agent, for the Greater China region. This follows positive Phase 3 study results.

• Achieves FY 2025 Revenue Guidance

  Telix reported unaudited Group revenue of approximately US$804 million for FY 2025, meeting its upgraded guidance of US$800-$820 million.

• Strong Q4 Performance and Gozellix Launch

  Q4 2025 unaudited Group revenue was approximately US$208 million, a 46% year-over-year increase, with Precision Medicine revenue up 4% quarter-over-quarter, driven by the successful U.S. launch of Gozellix®.

auto_awesomeAnalysis

The acceptance of the Illuccix NDA by the Chinese NMPA is a pivotal regulatory milestone, paving the way for commercialization in a strategically important and rapidly growing market for prostate cancer diagnostics. This significantly expands Telix's global footprint and future revenue potential. Simultaneously, the company's achievement of its upgraded FY 2025 revenue guidance, with strong Q4 growth and the successful U.S. launch of Gozellix, demonstrates robust commercial execution and financial health. These combined positive developments underscore Telix's strong product pipeline and market penetration capabilities, positioning it for continued growth.